DHGWA
ATNM icon

Dixon Hughes Goodman Wealth Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$0 Hold
33
– – ﹤0.01% 897
2021
Q4 		$0 Buy
+33
New +$248 ﹤0.01% 819

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's ATNM Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2022 at 33 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #897.

Dixon Hughes Goodman Wealth Advisors first reported a position in ATNM in Q4 2021 and has held it in 2 quarters since. 38 funds tracked by Wall St. Rank hold ATNM as of Q1 2022.

  • Dixon Hughes Goodman Wealth Advisors held 33 shares of Actinium Pharmaceuticals worth $0 as of Q1 2022.
  • Dixon Hughes Goodman Wealth Advisors left its Actinium Pharmaceuticals share count unchanged in Q1 2022.
  • Actinium Pharmaceuticals made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #897 holding.
  • Dixon Hughes Goodman Wealth Advisors first reported a position in Actinium Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • 38 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.